Publications by authors named "M Griese"

Background: Interstitial lung disease (ILD) is rarer in children (chILD) than adults, but with increasing diagnostic awareness, more cases are being discovered. chILD prognosis is often poor, but increasing numbers are now surviving into adulthood.

Aim: To characterize chILD-survivors and identify their impact on adult-ILD centers.

View Article and Find Full Text PDF
Article Synopsis
  • Interstitial lung diseases (ILDs) are complex and diverse conditions that affect both children and adults, with limited treatment options and a challenging diagnosis process often requiring invasive techniques.
  • The RARE-ILD initiative is a collaborative effort by experts to develop innovative non-invasive diagnostic methods and biomarkers, leveraging artificial intelligence for improved data analysis and understanding of ILDs across different ages.
  • The eurILDreg project collects extensive patient data using various assessments and technology, with an aim to enhance research, improve patient care, and potentially revolutionize the management of ILDs for up to 4,000 patients and 100,000 biospecimens.
View Article and Find Full Text PDF

The main monogenic causes of pulmonary fibrosis in adults are mutations in telomere-related genes. These mutations may be associated with extrapulmonary signs (hepatic, haematological and dermatological) and typically present radiologically as usual interstitial pneumonia or unclassifiable fibrosis. In children, the monogenic causes of pulmonary fibrosis are dominated by mutations in surfactant-related genes.

View Article and Find Full Text PDF

Background: Childhood interstitial lung disease (chILD) encompasses a group of rare heterogeneous respiratory conditions associated with significant morbidity and mortality. Reports suggest that many patients diagnosed with chILD continue to have potentially progressive or fibrosing disease into adulthood. Over the last decade, the spectrum of conditions within chILD has widened substantially, with the discovery of novel entities through advanced genetic testing.

View Article and Find Full Text PDF